Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 11, 2007

Ganymed to Use Selexis Tool to Manufacture Antibodies

  • Selexis signed a commercial license agreement with Ganymed Pharmaceuticals for use of Selexis' technology for large-scale production of Ganymed's lead antibodies.

    The deal allows Ganymed to use a high performance cell line, developed by Ganymed scientists using the Selexis SURE cell line development platform, for the clinical and commercial production of a number of products.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »